儿科门诊中注意力缺陷多动障碍药物的处方：对日本行政数据（2012 - 2018年）的回顾性调查
Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012-2018).
作者信息
Kikuchi Daisuke, Obara Taku, Tokunaga Misaki, Shiozawa Makoto, Takahashi Ai, Ito Misato, Hino Hiroaki, Miura Ryosuke, Hayakawa Sachiko, Watanabe Yoshiteru
机构信息
Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Japan; Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Japan.
Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Japan; Division of Preventive Medicine and Epidemiology, Tohoku University Tohoku Medical Megabank Organization, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Japan.
出版信息
Asian J Psychiatr. 2021 Mar;57:102512. doi: 10.1016/j.ajp.2020.102512. Epub 2021 Jan 15.
We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.
我们旨在阐明日本儿科门诊患者中注意力缺陷多动障碍（ADHD）药物的处方趋势。在2012年1月至2018年12月期间，我们评估了哌甲酯渗透泵控释口服制剂（OROS）、托莫西汀和胍法辛作为单一疗法的处方趋势。在男孩中，哌甲酯-OROS和托莫西汀的处方分别从46.5%降至37.2%以及从18.6%降至15.6%。胍法辛的处方从0.0%增至12.3%。在女孩中，哌甲酯-OROS的处方无显著差异（从37.0%降至26.4%）；然而，托莫西汀从23.1%降至16.3%，胍法辛从0.0%增至12.8%。在2012年至2018年期间，哌甲酯-OROS和托莫西汀的处方转变为胍法辛。
Zotero 插件